Cybin announces the publication bu WIPO of Cybin's patent application for psychedelics-based delivery systems.
Red Light Holland Appoints New Chief Marketing Officer
Red Light Holland's new Chief Marketing Officer, Ridley Doolittle, has extensive experience in brand development, including a senior position with Bacardi.
Awakn Successfully Completes Phase One of Its Drug Discovery Program
Awakn Life Sciences announces the completion of its "hit to lead" program on developing new chemical entities (NCE).
Red Light Holland CTIO, Sarah Hashkes, Publishes Microdosing Article and will be Participating in an Online Webinar by Harvard's Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center at Harvard Law School
Red Light Holland announces it is participating in a Harvard-sponsored online webinar on psychedelic drug law policy.
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
Field Trip announces receiving broad patent protection for its novel molecule, FT-104, from the USPTO.
The Next Big Addiction Treatment
Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mydecine Innovations reports its financial results for fiscal 2021 and updates investors on the company's R&D.
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
Novamind is expanding its psychedelics-based therapies into Brazil via its strategic partner in Latin America, Bienstar Wellness Corp.
Delic Expansion Accelerating into 2022 with New Clinic Openings
Delic Holdings announces two new clinics opening through its subsidiary, Ketmine Wellness Centers (KWC).
Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia
Albert Labs announces the filing of a provisional patent application for the production of Psilocybe mycelia and other fungi.
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.
